Brief: Topline Results From Palm 007 Study Of Siga’S Tecovirimat In Treatment Of Mpox

SIGA Technologies

15/08/2024 12:49

Aug 15 (Reuters) - SIGA Technologies Inc  SIGA.O :
    * TOPLINE RESULTS FROM PALM 007 STUDY OF SIGA’S TECOVIRIMAT
IN
TREATMENT OF MPOX RELEASED
    * STUDY DID NOT REACH STATISTICAL SIGNIFICANCE
    * RESULTS AFFIRM TECOVIRIMAT'S STRONG SAFETY PROFILE
    * STUDY DID NOT MEET PRIMARY ENDPOINT
    * MULTIPLE ADDITIONAL CLINICAL TRIALS EVALUATING TECOVIRIMAT
FOR
MPOX CONTINUE
    * MISSING PRIMARY ENDPOINT NOT ENTIRELY UNEXPECTED AS STUDY
POPULATION WAS HOSPITALIZED DURING TREATMENT WITH HIGH LEVEL OF
SUPPORTIVE CARE
    * MISSING PRIMARY ENDPOINT ALSO NOT ENTIRELY UNEXPECTED AS
MANY OF
STUDY POPULATION PRESENTED FOR TREATMENT OVER A WEEK AFTER
ILLNESS STARTED

Source text for Eikon:  ID:nGNXnYMqZ 
Further company coverage:  SIGA.O 

 ((Reuters.Briefs@thomsonreuters.com;))